- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
Patent holdings for IPC class A61P 25/18
Total number of patents in this class: 3424
10-year publication summary
|
84
|
114
|
173
|
206
|
185
|
213
|
225
|
209
|
198
|
137
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2704 |
95 |
| Janssen Pharmaceutica N.V. | 3367 |
66 |
| F. Hoffmann-La Roche AG | 7946 |
61 |
| H. Lundbeck A/S | 1250 |
53 |
| Taisho Pharmaceutical Co., Ltd. | 863 |
42 |
| Intra-Cellular Therapies, Inc. | 413 |
40 |
| Glaxo Group Limited | 4132 |
38 |
| Boehringer Ingelheim International GmbH | 4644 |
36 |
| AstraZeneca AB | 2872 |
35 |
| Pfizer Inc. | 3396 |
34 |
| Sumitomo Dainippon Pharma Co., Ltd. | 212 |
32 |
| Hoffmann-La Roche Inc. | 3489 |
30 |
| Astellas Pharma Inc. | 1071 |
26 |
| Sage Therapeutics, Inc. | 370 |
26 |
| Sunovion Pharmaceuticals Inc. | 260 |
25 |
| Otsuka Pharmaceutical Co., Ltd. | 1503 |
23 |
| Vanda Pharmaceuticals, Inc. | 367 |
23 |
| Merck Sharp & Dohme LLC | 3737 |
23 |
| Dainippon Sumitomo Pharma Co., Ltd. | 181 |
22 |
| Neurocrine Biosciences, Inc. | 416 |
21 |
| Other owners | 2673 |